Ligand Pharmaceuticals (LGND) Free Cash Flow (2010 - 2026)

Ligand Pharmaceuticals has disclosed Free Cash Flow across 17 years of filings, most recently posting $48.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $48.5 million, up 288.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.3 million (up 134.4% YoY), and the FY2025 annual result was $49.1 million, down 49.32% from the prior year.
• Free Cash Flow came in at $48.5 million for Q1 2026 at Ligand Pharmaceuticals, up from $45.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $111.2 million in Q3 2024 to a low of -$61.7 million in Q2 2024.
• The 5-year median for Free Cash Flow is $18.7 million (2024), against an average of $22.3 million.
• Peak annual rise in Free Cash Flow reached 2092.37% in 2024, while the deepest fall reached 12913.5% in 2024.
• Ligand Pharmaceuticals' Free Cash Flow stood at $54.8 million in 2022, then tumbled by 79.61% to $11.2 million in 2023, then jumped by 156.86% to $28.7 million in 2024, then surged by 59.29% to $45.7 million in 2025, then advanced by 6.05% to $48.5 million in 2026.
• The last three Free Cash Flow figures came in at $48.5 million (Q1 2026), $45.7 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.